While inhibitors of PKM2 reduce glycolysis and the Warburg effect, activators do the opposite, constitutively forcing PKM2 into its tetrameric form and starving cancer cells of the anabolic intermediates they were otherwise building for tumor proliferation. This evidence concerns the gene PKM and cancer.